P492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML-1)

• E. Stein,
• S. de Botton,
• A. Pigneux,
• C. McMahon,
• B. Ball,
• G. Borthakur,
• A. Eghtedar,
• S. Kambhampati,
• J. Tache,
• E. Wang,
• H. Kelley,
• A. Volkert,
• K. Baker,
• Q. Kang-Fortner,
• G. Hodgson,
• C. Madigan,
• E. Warlick,
• D. Roth,
• M. Kelly,
• D. Pollyea

Affiliations

E. Stein

1 Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, United States of America

S. de Botton

2 Institut Gustave Roussy, Paris

A. Pigneux

3 CHU de Bordeaux - Hôpital Haut-Lévèque, Bordeaux, France

C. McMahon

4 University of Colorado, Aurora

B. Ball

5 City of Hope, Duarte

G. Borthakur

6 Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston

A. Eghtedar

7 Colorado Blood Cancer Institute, Sarah Cannon Research Institution, Denver

S. Kambhampati

8 HCA Midwest Research Medical Center, Sarah Cannon Research Institution, Kansas City

J. Tache

9 BRCR Global, Plantation

E. Wang

10 Roswell Park, Buffalo

H. Kelley

11 Syros, Cambridge, United States of America

A. Volkert

11 Syros, Cambridge, United States of America

K. Baker

11 Syros, Cambridge, United States of America

Q. Kang-Fortner

11 Syros, Cambridge, United States of America

G. Hodgson

11 Syros, Cambridge, United States of America

C. Madigan

11 Syros, Cambridge, United States of America

E. Warlick

11 Syros, Cambridge, United States of America

D. Roth

11 Syros, Cambridge, United States of America

M. Kelly

11 Syros, Cambridge, United States of America

D. Pollyea

4 University of Colorado, Aurora